4-(9-(3,3-DIFLUOROCYCLOPENTYL)-5,7,7-TRIMETHYL-6-OXO-6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-B[1,4]DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES
Disclosed is a compound of formula (I) where the substituents are as disclosed in the description. Examples of compounds of formula (I) are N-cyclopropyl-4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamide 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5Hpyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(3-fluorocyclopentyl)-3-methoxybenzamide and N-(3,3-difluorocyclopentyl)-4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamide. Also disclosed is a pharmaceutical composition comprising a compound of formula (I), the use of a compound of formula (I) in the manufacture of a medicament for inhibiting protein kinase activity, a method for inhibiting protein kinase activity in a biological sample and a process for preparing a compound of formula (I).
